Aquestive Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Aquestive Therapeutics with an Overweight rating and $10 price target. Aquestive is “on the cusp” of “transformative value creation” with the advancement of its proprietary oral film products for its own commercial portfolio, the analyst tells investors in a research note. The firm says the company’s lead value driver Anaphylm, a sublingual film form of epinephrine for the emergency treatment of allergic reactions, including anaphylaxis, has the potential to significantly expand a rescue space that historically has been highly underpenetrated.